Loading...
Market
Phase 3 trial announcement for VK2809 by end of Q1 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Viking Therapeutics
Story
Viking Therapeutics Reports Positive Phase 2b Results for VK2809 in NASH Patients: 75% NASH Resolution, 57% Fibrosis Improvement
Jun 4, 2024, 11:08 AM
Viking Therapeutics (VKTX) has announced positive results from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed Non-Alcoholic Steatohepatitis (NASH). The study revealed that up to 75% of patients treated with VK2809 achieved NASH resolution with no worsening of fibrosis, compared to 29% for the placebo group. Additionally, 57% of VK2809-treated patients achieved a one-stage improvement in fibrosis with no worsening of NASH. These results highlight VKTX's superior efficacy and safety profile compared to competitors, such as Madrigal Pharmaceuticals (MDGL). VKTX's safety profile is comparable to placebo, with no discontinuations reported, unlike GPCR, which has shown a high incidence of vomiting (62%) and study discontinuations. VKTX is also targeting the obesity market, showing impressive results with 6.2% weight loss and a significant potential for market growth.
View original story
Similar markets
Additional Phase 3 trials • 33%
FDA Approval without additional trials • 33%
FDA Rejection • 33%
Phase 3 trial initiation • 33%
Phase 3 trial completion • 33%
FDA submission • 34%
Pre-clinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 or beyond • 25%
Phase 4 trial initiated • 33%
Additional Phase 3 trial initiated • 33%
No further trials announced • 33%
FDA approval application • 25%
Partnership with another company • 25%
Further clinical trials • 25%
No significant action • 25%
